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INTRODUCTION
Mesenchymal stem cells (MSCs) are cells that have been
demonstrated to have the ability to differentiate into distinct
mesenchymal tissues such as bones, tendons, muscles, adi-
pose tissues, cartilage and nerve tissues as well as to support
hematopoiesis (1-5). MSCs have been labeled in a variety of
ways since Dexter named them ‘stromal cells’ in the 1980’s
(6). Caplan designated the term mesenchymal stem cells in
the 1990’s (7), while others still refer to them as marrow stro-
mal cells. The methods used for preparation of these cells
have not yet been standardized; the differential potential of
MSCs has not yet been fully determined due to the limita-
tions of in vitro expansion. Since Noort et al. reported that
MSCs promote engraftment of umbilical cord blood-derived
CD34+cells in non-obese diabetic/severe combined immun-
odeficiency (NOD/SCID) mice (8, 9) many clinical trials have
been pursued to better understand their role in bone marrow
transplantation (10). Unlike transplantation of hematopoi-
etic stem cells (HSCs) only, the questions regarding in vitro
expansion remain unanswered; in particular, questions regard-
ing the optimal infusion buffer and whether to use thawed
cells or fresh detached cells for cotransplantation of MSCs
and HSCs remain unanswered. We studied the optimal ratio
of HSCs to MSCs to facilitate engraftment, and tried to deter-
mine the appropriate ratio for enhancement of HSCs. 
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Cotransplanted Bone Marrow Derived Mesenchymal Stem Cells (MSC)
Enhanced Engraftment of Hematopoietic Stem Cells in a MSC-dose
Dependent Manner in NOD/SCID Mice
Transplantation of marrow-derived mesenchymal stem cells (MSCs), expanded by
culture in addition to whole bone marrow, has been shown to enhance engraftment
of human hematopoietic stem cells (HSCs). Our hypothesis was that there might
be an optimum ratio range that could enhance engraftment. We examined the per-
cent donor chimerism according to the ratio of HSCs to MSCs in non-obese diabetic/
severe combined immunodeficiency (NOD/SCID) mice. We tested a series of ratios
of co-transplanted CD34+-selected bone marrow cells, and marrow-derived MSCs
into sublethally irradiated NOD/SCID mice. In all experiments, 1×10
5 bone marrow
derived human CD34+ cells were administered to each mouse and human MSCs
from different donors were infused concomitantly. We repeated the procedure three
times and evaluated engraftment with flow cytometry four weeks after each trans-
plantation. Serial ratios of HSCs to MSCs were 1:0, 1:1, 1:2 and 1:4, in the first ex-
periment, 1:0, 1:1, 1:2, 1:4 and 1:8 in the second and 1:0, 1:1, 1:4, 1:8 and 1:16 in
the third. Cotransplantation of HSCs and MSCs enhanced engraftment as the dose
of MSCs increased. Our results suggest that the optimal ratio of HSCs and MSCs
for cotransplantation might be in the range of 1:8-1:16; whereas, an excessive dose
of MSCs might decrease engraftment efficiency.
Key Words : Hematopoietic Stem Cells; Mesenchymal Stem Cells; Transplantation; Mice, SCID; Engraftment
Received : 8 March 2006
Accepted : 16 May 2006Cotransplantation of Bone Marrow Derived MSCs and HSCs in NOD/SCID Mice 1001
MATERIALS AND METHODS
Human CD34+ cells and MSCs isolation
Human CD34+ cells were collected by bone marrow aspi-
ration from 34 to 57 yr-old healthy volunteers (Table 1) under
an Institutional Review Board approval protocol of Samsung
Medical Center, Korea. CD34+ cells were isolated using the
MACS sort system (Miltenyi Biotec GmbH, Germany). The
purity of the CD34+-selected cells was more than 90%. MSCs
were cultured as previously described (11). We used bone
marrow derived MSCs that were not exceeded over 3 passages.
MSCs were confirmed to be negative for hematopoietic mar-
kers by flow cytometry. For further clarification of MSCs, the
following antibodies were used: CD14 (BD-Pharmingen,
Palo Alto, CA, U.S.A.), CD29, CD34, CD44, CD45, CD51-
61, CD90, CD105, CD106, CD166, HLA-DR, Stro-1, SH2-
M2, SH3-M2 and SH4-M2.
Cotransplantation of MSCs and HSCs into NOD/SCID
mouse
NOD/SCID mice, purchased from Jackson Laboratories
(MA, U.S.A.) were maintained in microisolator cages in spe-
cific pathogen free conditions. Eight-week old mice received
sublethal total-body irradiation with 300 cGy from 137-Cs
source within 24 hr before transplantation. In all experiments,
1×105 bone marrow derived human CD34+ cells were ad-
HSCs
Sex Age (yr)
MSCs
Sex Age (yr)
Exp. 1 Male 40 Male 35
Exp. 2 Male 35 Male 34
Exp. 3 Female 57 Male 35
Table 1. Donor information of each experiment
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Fig. 1. Isolation of HSCs from bone marrow and results of FACS analyses. HSCs were isolated by MACS sort system from bone marrow.
The purity of HSCs infused to NOD/SCID mice was more than 90%. (A) Isotypes were stained with FITC-anti-mouse IgG1 and PE-anti-
mouse IgG1. (B) Dot plots show FITC-anti-human CD34 on x-axis and PE-anti-human CD38 on y-axis. (C) Isolated CD34+ cells were sta-
ined PE-anti-human CD34 only on y-axis.  
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Fig. 2. Results of MSCs phenotypes by FACS analysis. MSCs that
were used in this test were positive for CD29 (BD-Pharmingen,
Palo Alto, CA, U.S.A.), CD44, CD90, CD105, CD166, SH2, SH3,
and SH4, while negative for CD14, CD34, CD45, CD51-61, CD106
and HLA-DR. Stro-1 was weakly expressed. Blank peaks indicate
the isotype of each cell and closed peaks represent expression
of each marker. 1002 D.H. Kim, K.H. Yoo, Y.S. Yim, et al.
ministered to each mouse and MSCs were used concomitantly.
Bone marrow derived CD34+ cells and MSCs were inject-
ed in a final volume of 500 to 1,000  L HBSS (Bio-Whit-
taker, Baltimore, MD, U.S.A.) per mouse and were infused
via tail vein injection. Three experiments were performed
repeatedly. Serial ratios of bone marrow derived CD34+ cells
to MSCs were 1:0, 1:1, 1:2 and 1:4, in the first experiment
(4 mice), 1:0, 1:1, 1:2, 1:4 and 1:8 in the second (10 mice)
and 1:0, 1:1, 1:4, 1:8 and 1:16 in the third (15 mice).
Analysis of human CD34+ cell engraftment
Mice were sacrificed 4 weeks posttransplant and cells from
the bone marrow were analyzed by flow cytometry. Cells were
then incubated with PE-mouse anti-human CD45 (BD-Phar-
mingen, Palo Alto, CA, U.S.A.) for 30 min at 4℃, washed,
resuspended in 1% paraformaldehyde in phosphate-buffered
saline, and analyzed on a flow cytometry (FACS Vantage,
Becton Dickinson, Palo Alto, CA, U.S.A.). 
Statistical analysis
Mann-Whitney test (SPSS 12.0 for Windows. SPSS Inc.)
was used to calculate differences between the HSCs only group
and the cotransplant group. A p-value of less than 0.05 was
considered statistically significant.
RESULTS
The immunophenotye of bone marrow derived HSCs 
We isolated CD34+ HSCs from bone marrow using CD-
34+ cell directed kit (Miltenyi Biotec GmbH, Germany),
and at the same time, isolated MSCs from CD34-population.
The CD34+cells infused had purities over 90% and CD34+/
CD38- cells were in the range of 30±5-40±5% (data not
shown) (Fig. 1). 
The immunophenotyes of bone marrow derived MSCs
FACS results showed that CD29, CD44, CD90, CD105,
CD166, SH2, SH3, and SH4 were expressed in more than
90% of MSCs. Typical hematopoietic antigens (CD14, CD34
and CD45) as well as CD51-61, CD106 and HLA-DR known
to be negative markers for MSCs (2, 12, 13) were hardly ex-
pressed. On the other hand, Stro-1, known to be related with
homing to bone marrow (14), was expressed in 3.14% of
MSCs (Fig. 2).
Effect of MSCs on engraftment according to cell dose 
We observed that the engraftment efficiency after cotrans-
plantation was improved as the MSCs dose was increased up
to a certain level in all three independent experiments. The
Fig. 3. MSCs enhanced human cell engraftment in bone marrow of NOD/SCID mice in a dose-dependent manner at 4 weeks posttrans-
plant. (A) CD34+ only group (1.0×10
5 cells). (B) The ratio of CD34+ to MSCs was 1:1 (1.0×10
5 cells each). (C) The ratio of CD34+ to MSCs
was 1:2 (1.0×10
5:2.0×10
5 cells). (D) The ratio of CD34+ to MSC was 1:4 (1.0×10
5:4.0×10
5 cells). (E) The ratio of CD34+ to MSC was 1:8
(1.0×10
5:8.0×10
5 cells). This is representative of 2 analyses in the experiment 2.
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engraftment fold-increase of the 1:4 group was 3.99, 19.78
and 6.03 compared to the HSCs only group in experiment
1, 2 and 3, respectively (Table 2). The percent donor chime-
rism of the 1:16 group was inferior to that of the 1:8 ratio
group (Fig. 3). The 1:4 and 1:8 ratio groups were associated
with a higher percent donor chimerism than any other group
studied (Fig. 4).
DISCUSSION
MSCs have recently been used experimentally in clinical
trials of cardiovascular repair (15, 16), treatment of lung fibro-
sis (17), spinal cord injury (18) and bone and cartilage repair
(4, 19) as a stem cell source. MSCs have been successfully used
for therapeutic application when they are derived from bone
marrow (20). 
Generally, an accepted range of HSC dose for engraftment
after bone marrow transplantation is 3-4×106CD34+cells/kg
of recipient body weight for humans. Considering that a mouse
weighs about 30 g on average, we postulated that 9-12×104
CD34+ cells should be a reasonable dose range for a mouse,
and therefore infused 1×105 CD34+ cells.
Usually, the fluorescence intensity of CD34+ cells when
conjugated with FITC is weaker than that when conjugated
with PE using flow cytometry. Therefore, it is a matter of
course that the percentage of CD34+ fraction may is differ-
ent to some extent according to the conjugated materials even
though the testing samples are exactly the same. Authors usu-
ally evaluate the purity of overall CD34+cell fraction stained
with PE according to the manufacturer’s protocol of CD34
sort kit (Miltenyi Biotec, Germany). Fig. 1B is intended to
show the percentage of CD34+/CD38- fraction which is
known to be more primitive and have higher engraftment
potential than CD34+/CD38+ fraction using PE-conjugat-
ed CD38 and FITC-conjugated CD34.
At present we do not know how long MSCs will maintain
innate characteristics including the ability to differentiate and
cytokine production; nor do we know what the best compo-
sition culture media should contain for maintaining MSCs.
We used early MSCs not exceeding 3 passages based on the
assumption that early passage cells would be more likely to
have the innate characteristics of MSCs.
Cotransplantation of HSCs and MSCs enhanced engraft-
ment as the dose of the MSCs were increased up until a 1:8
ratio. The percent donor chimerism in the 1:16 group, how-
ever, was lower than that of the 1:8 group even though it was
still higher than the HSCs only group as shown in the expe-
riment 3. These findings suggest that HSCs and MSCs have
a threshold ratio of HSCs to MSCs for enhancing engraftment
when cotransplanted into a NOD/SCID mouse. Our findings
suggest that the optimal ratio of HSCs to MSCs in cotrans-
plantation might be between 1:8 and 1:16 and we are con-
ducting further experiments using these ratios. We confirmed
MSCs engraftment enhancing ability in 3 experiments. Each
experiment was performed with bone marrow-derived MSCs
obtained from a different volunteer donor, and showed differ-
ent enhancing abilities. For example, the mean fold-increase
of the 1:4 ratio group was 3.99 compared with the HSCs only
group in the experiment 1, while it was 7.21 in the experi-
ment 2, and 1.21 in the experiment 3. The CD34+cells were
Fig. 4. Results of contransplantation. In all experiments, the engraftment in bone marrow was increased as the MSCs dose was increased.
In experiment 3, the engraftment in the group of a 1:16 ratio is inferior to that of a 1:8 ratio. *Indicates significant statistical difference between
the CD34+ only group and a cotransplanted group.
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Ratio of HSC and MSC
Exp. 3 Exp. 2 Exp. 1
*
Ratio (HSCs:MSCs)
% of engraftment in bone marrow
No. of
mouse/ratio
group
1:0 1:1 1:2 1:4 1:8 1:16
CD34+ dose 1 1 1 1 1 1
(×10
5)
MSCs dose 0 1 2 4 8 16
(×10
5)
Exp. 1 2.66 3.62 6.57 10.62 NA NA 1
Exp. 2 0.6 1.26 1.08 3.61 6.62 NA 2
* 3.1 8.28 5.04 5.25
Exp. 3 0.59 0.64 NA 1.29 4.55 1.67 3
1.25 0.26 1.68 5.64 2.35
1.73 2.56 1.35 11.34 3.43
Table 2. Summary of bone marrow engraftment
NA, not applicable. *, expired at 2 weeks later after transplantation.1004 D.H. Kim, K.H. Yoo, Y.S. Yim, et al.
also derived from different donors; however, it is unlikely that
the quality of MSCs is the sole determinant of engraftment
efficiency. It is clear that the CD34+cell dose has been shown
to be strongly associated with engraftment kinetics regard-
less of individual differences (21, 22). 
In addition, the proliferation rate and morphology of the
3 MSCs experiments differed when observed during cell ex-
pansion before cotransplantation (data not shown). There-
fore, our findings suggest that the engraftment enhancing
ability of MSCs might have considerable difference accord-
ing to the MSC donor. 
Our study demonstrated that MSCs could enhance engraft-
ment in a dose-dependent manner up to a certain level in
NOD/SCID mice. Future studies should help elucidate fur-
ther mechanisms associated with engraftment such as secre-
tion of specific MSC-cytokines that help enhance engraft-
ment. For clinical application to human patients character-
istics of MSCs including immunosuppression and HLA res-
triction require further explanation. 
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